The late Na current as a therapeutic target: Where are we?

Journal of Molecular and Cellular Cardiology

Volumn 61, Issue , 2013, Pages 44-50

  Maier, Lars S ^a   Sossalla, Samuel ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Angina; Arrhythmias; Heart failure; INa,late; Ischemia; Ranolazine

Indexed keywords

6 [4 (TRIFLUOROMETHOXY)PHENYL] 3 (TRIFLUOROMETHYL) [1,2,4]TRIAZOLO[4,3 A]PYRIDINE; AMIODARONE; ATENOLOL; CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CHANNEL L TYPE; DRONEDARONE; ENALAPRIL; F 15845; FLECAINIDE; LIDOCAINE; METOPROLOL; MEXILETINE; PLACEBO; RANOLAZINE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.5; SODIUM ION; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ARTIFICIAL HEART PACEMAKER; CARDIOVERSION; CHANNEL GATING; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEPOLARIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART STROKE VOLUME; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; LONG QT SYNDROME; NONHUMAN; PATCH CLAMP; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINUS RHYTHM; SODIUM CURRENT; SUSTAINED RELEASE FORMULATION; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

ANGINA; ARRHYTHMIAS; HEART FAILURE; I(NA,LATE); ISCHEMIA; RANOLAZINE;

ANIMALS; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; CALCIUM; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; SODIUM CHANNEL BLOCKERS;

ANGINA;

EID: 84880330010     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.03.001     Document Type: Review

References (82)

1. Saint D.A., Ju Y.K., Gage P.W. A persistent sodium current in rat ventricular myocytes. J Physiol 1992, 453:219-231.
2. Coraboeuf E., Deroubaix E., Coulombe A. Effect of tetrodotoxin on action potentials of the conducting system in the dog heart. Am J Physiol Heart Circ Physiol 1979, 236:H561-H567.
3. Attwell D., Cohen I., Eisner D., Ohba M., Ojeda C. The steady state TTX-sensitive ("window") sodium current in cardiac Purkinje fibres. Pflugers Arch 1979, 379:137-142.
4. Ju Y.K., Saint D.A., Gage P.W. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol 1996, 497:337-347.
5. Undrovinas A.I., Fleidervish I.A., Makielski J.C. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res 1992, 71:1231-1241.
6. Wu J., Corr P.B. Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. Am J Physiol 1994, 266:H1034-H1046.
7. Ward C.A., Giles W.R. Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. J Physiol 1997, 500(Pt 3):631-642.
8. Belardinelli L., Shryock J.C., Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006, 92(Suppl. 4):iv6-iv14.
9. + current in human ventricle: implications for sodium loading and homeostasis. J Cardiovasc Electrophysiol 2006, 17(Suppl. 1):S15-S20.
10. Hasenfuss G., Maier L.S. Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol 2008, 97:222-226.
11. Na in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 2004, 44:192-199.
12. Song Y., Shryock J.C., Wagner S., Maier L.S., Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther 2006, 318:214-222.
13. Sossalla S., Wagner S., Rasenack E.C., Ruff H., Weber S.L., Schondube F.A., et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts - role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008, 45:32-43.
14. + channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes. Circ Res 2006, 99:1225-1232.
15. Maltsev V.A., Silverman N., Sabbah H.N., Undrovinas A.I. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail 2007, 9:219-227.
16. Huang B., El-Sherif T., Gidh-Jain M., Qin D., El-Sherif N. Alterations of sodium channel kinetics and gene expression in the postinfarction remodeled myocardium. J Cardiovasc Electrophysiol 2001, 12:218-225.
17. Ahern G.P., Hsu S.F., Klyachko V.A., Jackson M.B. Induction of persistent sodium current by exogenous and endogenous nitric oxide. J Biol Chem 2000, 275:28810-28815.
18. + channels. J Clin Invest 2006, 116:3127-3138.
19. Hund T.J., Koval O.M., Li J., Wright P.J., Qian L., Snyder J.S., et al. A beta(IV)-spectrin/CaMKII signaling complex is essential for membrane excitability in mice. J Clin Invest 2010, 120:3508-3519.
20. 2+/calmodulin-dependent protein kinase II in guinea-pig ventricular myocytes. Cardiovasc Res 2010, 85:454-463.
21. Yao L., Fan P., Jiang Z., Viatchenko-Karpinski S., Wu Y., Kornyeyev D., et al. Nav1.5-dependent persistent Na+influx activates CaMKII in rat ventricular myocytes and N1325S mice. Am J Physiol Cell Physiol 2011, 301:C577-C586.
22. Ashpole N.M., Herren A.W., Ginsburg K.S., Brogan J.D., Johnson D.E., Cummins T.R., et al. Ca2+/calmodulin-dependent protein kinase II (CaMKII) regulates cardiac sodium channel NaV1.5 gating by multiple phosphorylation sites. J Biol Chem 2012, 287:19856-19869.
23. Fischer T.H., Maier L.S., Sossalla S. The ryanodine receptor leak: how a tattered receptor plunges the failing heart into crisis. Heart Fail Rev 2012, [Epub ahead of print Aug 30].
24. Moreno J.D., Clancy C.E. Pathophysiology of the cardiac late Na current and its potential as a drug target. J Mol Cell Cardiol 2012, 52:608-619.
25. Wasserstrom J.A., Salata J.J. Basis for tetrodotoxin and lidocaine effects on action potentials in dog ventricular myocytes. Am J Physiol 1988, 254:H1157-H1166.
26. Sossalla S., Maier L.S. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther 2012, 133:311-322.
27. Antzelevitch C., Belardinelli L., Zygmunt A.C., Burashnikov A., Di Diego J.M., Fish J.M., et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004, 110:904-910.
28. Undrovinas A.I., Belardinelli L., Undrovinas N.A., Sabbah H.N. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 2006, 17(Suppl. 1):S169-S177.
29. Beyder A., Strege P.R., Reyes S., Bernard C.E., Terzic A., Makielski J., et al. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action. Circulation 2012, 125:2698-2706.
30. Strege P., Beyder A., Bernard C., Crespo-Diaz R., Behfar A., Terzic A., et al. Ranolazine inhibits shear sensitivity of endogenous Na+current and spontaneous action potentials in HL-1 cells. Channels (Austin) 2012, 6:457-462.
31. Belardinelli L., Antzelevitch C., Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodiumdependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J 2004, 6(Suppl. I):13-17.
32. Pignier C., Rougier J.S., Vie B., Culie C., Verscheure Y., Vacher B., et al. Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. Br J Pharmacol 2010, 161:79-91.
33. Bers D.M. Excitation-contraction coupling and cardiac contractile force 2001, Kluwer Academic Publishers, Dordrecht, Netherlands. 2nd ed.
34. 2+ exchanger overexpression predisposes to reactive oxygen species-induced injury. Cardiovasc Res 2003, 60:404-412.
35. Wang P., Fraser H., Lloyd S.G., McVeigh J.J., Belardinelli L., Chatham J.C. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther 2007, 321:213-220.
36. Zhang X.Q., Yamada S., Barry W.H. Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia. J Cardiovasc Pharmacol 2008, 51:443-449.
37. Fraser H., Belardinelli L., Wang L., Light P.E., McVeigh J.J., Clanachan A.S. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 2006, 41:1031-1038.
38. + currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 2010, 55:2330-2342.
39. Hwang H., Arcidi J.M., Hale S.L., Simkhovich B.Z., Belardinelli L., Dhalla A.K., et al. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation 2009, 120:S16-S21.
40. Rastogi S., Sharov V.G., Mishra S., Gupta R.C., Blackburn B., Belardinelli L., et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 2008, 295:H2149-H2155.
41. + current. Basic Res Cardiol 2011, 106:263-272.
42. Venkataraman R., Belardinelli L., Blackburn B., Heo J., Iskandrian A.E. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging 2009, 2:1301-1309.
43. Gralinski M.R., Black S.C., Kilgore K.S., Chou A.Y., McCormack J.G., Lucchesi B.R. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res 1994, 28:1231-1237.
44. Rousseau M.F., Pouleur H., Cocco G., Wolff A.A. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005, 95:311-316.
45. Morrow D.A., Scirica B.M., Karwatowska-Prokopczuk E., Murphy S.A., Budaj A., Varshavsky S., et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007, 297:1775-1783.
46. Maltsev V.A., Undrovinas A. Late sodium current in failing heart: friend or foe?. Prog Biophys Mol Biol 2008, 96:421-451.
47. Maltsev V.A., Reznikov V., Undrovinas N.A., Sabbah H.N., Undrovinas A. Modulation of late sodium current by Ca2+, calmodulin, and CaMKII in normal and failing dog cardiomyocytes: similarities and differences. Am J Physiol Heart Circ Physiol 2008, 294:H1597-H1608.
48. Sabbah H.N., Chandler M.P., Mishima T., Suzuki G., Chaudhry P., Nass O., et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002, 8:416-422.
49. 2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res 2010, 107:1150-1161.
50. Na Augmentation Leading to Cellular Na and Ca Overload. Circ Res 2011, 108:555-565.
51. Na and cause ventricular diastolic dysfunction. J Pharmacol Exp Ther 2009, 330:550-557.
52. Maruyama K., Hara A., Hashizume H., Ushikubi F., Abiko Y. Ranolazine attenuates palmitoyl-l-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol 2000, 52:709-715.
53. Hayashida W., van Eyll C., Rousseau M.F., Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994, 8:741-747.
54. Moss A.J., Zareba W., Schwarz K.Q., Rosero S., McNitt S., Robinson J.L. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 2008, 19:1289-1293.
55. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, et al. RAnoLazIne for the treatment of Diastolic Heart Failure in pa-tients with preserved ejection fraction: The RALI-DHF proof-of-concept study. JACC: Heart Fail in press.
56. Coppini R., Ferrantini C., Yao L., Fan P., Del Lungo M., Stillitano F., et al. Late sodium current inhibition reverses electro-mechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 2012, 127:575-584.
57. Antzelevitch C., Belardinelli L. The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. J Cardiovasc Electrophysiol 2006, 17(Suppl. 1):S79-S85.
58. Cheng H., Lederer W.J. Calcium sparks. Physiol Rev 2008, 88:1491-1545.
59. Song Y., Shryock J.C., Belardinelli L. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol 2008, 294:H2031-H2039.
60. Wu L., Shryock J.C., Song Y., Li Y., Antzelevitch C., Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 2004, 310:599-605.
61. Dhalla A.K., Wang W.Q., Dow J., Shryock J.C., Belardinelli L., Bhandari A., et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2009, 297:H1923-H1929.
62. Morita N., Lee J.H., Xie Y., Sovari A., Qu Z., Weiss J.N., et al. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J Am Coll Cardiol 2011, 57:366-375.
63. Wu L., Shryock J., Song Y., Belardinelli L. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther 2006, 718-726.
64. + current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol 2010, 55:801-809.
65. Kumar K., Nearing B.D., Bartoli C.R., Kwaku K.F., Belardinelli L., Verrier R.L. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J Cardiovasc Electrophysiol 2008, 19:1073-1079.
66. Antzelevitch C., Sicouri S., Litovsky S.H., Lukas A., Krishnan S.C., Di Diego J.M., et al. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res 1991, 69:1427-1449.
67. NaCa contributes to electrical heterogeneity within the canine ventricle. Am J Physiol Heart Circ Physiol 2000, H1671-H1678.
68. Wilson S.R., Scirica B.M., Braunwald E., Murphy S.A., Karwatowska-Prokopczuk E., Buros J.L., et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 trial. J Am Coll Cardiol 2009, 53:1510-1516.
69. Scirica B.M., Morrow D.A., Hod H., Murphy S.A., Belardinelli L., Hedgepeth C.M., et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007, 116:1647-1652.
70. Bunch T.J., Mahapatra S., Murdock D., Molden J., Weiss J.P., May H.T., et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol 2011, 34:1600-1606.
71. 2+ currents and human atrial fibrillation. Circ Res 1999, 85:428-436.
72. Nattel S., Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J 2012, 33:1870-1877.
73. 2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res 2010, 106:1134-1144.
74. Burashnikov A., Di Diego J.M., Zygmunt A.C., Belardinelli L., Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007, 116:1449-1457.
75. Kumar K., Nearing B.D., Carvas M., Nascimento B.C., Acar M., Belardinelli L., et al. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 2009, 20:796-802.
76. Carvas M., Nascimento B.C., Acar M., Nearing B.D., Belardinelli L., Verrier R.L. Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart. J Cardiovasc Pharmacol 2010, 55:286-291.
77. Frommeyer G., Schmidt M., Clauss C., Kaese S., Stypmann J., Pott C., et al. Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure. Eur J Heart Fail 2012, 14:1322-1331.
78. Sicouri S., Glass A., Belardinelli L., Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008, 5:1019-1026.
79. Sicouri S., Burashnikov A., Belardinelli L., Antzelevitch C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol 2010, 3:88-95.
80. Burashnikov A., Sicouri S., Di Diego J.M., Belardinelli L., Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010, 56:1216-1224.
81. Murdock D.K., Kersten M., Kaliebe J., Larrain G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J 2009, 9:260-267.
82. Fragakis N., Koskinas K.C., Katritsis D.G., Pagourelias E.D., Zografos T., Geleris P. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol 2012, 110:673-677.